Profile ng asset
bevacizumab-vikg · Outlook Therapeutics, Inc. (OTLK)
- Indikasyon
- basang AMD
- Kilala rin bilang
- ONS-5010, LYTENAVA, bevacizumab gamma, Lytenava
Kumpanya
OTLKOutlook Therapeutics, Inc.
OTLKOutlook Therapeutics, Inc.Ang Outlook Therapeutics Inc. ay isang biopharmaceutical company na nasa clinical stage na nakatuon sa pagbuo at pag-komersyalisa ng ONS-5010, isang monoclonal antibody, o mAb, para sa iba't ibang mga indikasyon sa ophthalmology. Nakatanggap ang Kumpanya ng pa…
Nasa kalendaryo
29
Hul 2026
Hul 29, 2026
49 araw na ang nakalipas
OTLKOutlook Therapeutics, Inc.Timeline
Pinakabago muna.
Decision-grade
Hul 24, 2026
09:01 PM
OTLKOutlook Therapeutics, Inc.Decision-grade
Hul 24, 2026
12:00 AM
OTLKOutlook Therapeutics, Inc.Materyal
Hun 16, 2026
12:46 PM
OTLKOutlook Therapeutics, Inc.Materyal
Hun 16, 2026
12:02 PM
OTLKOutlook Therapeutics, Inc.Materyal
Hun 1, 2026
01:15 PM
OTLKOutlook Therapeutics, Inc.Materyal
Hun 1, 2026
12:46 PM
OTLKOutlook Therapeutics, Inc.Decision-grade
May 26, 2026
11:15 AM
OTLKOutlook Therapeutics, Inc.Materyal
Abr 7, 2026
08:15 PM
OTLKOutlook Therapeutics, Inc.Decision-grade
Dis 19, 2025
01:30 PM
OTLKOutlook Therapeutics, Inc.Nakarehistrong trial
| Registry ID | Phase | Status | Primary completion | Enrollment | Sites |
|---|---|---|---|---|---|
| NCT06190093 | Phase 3 | Tapos na | Nob 7, 2024 | 400 | 61 sa 61 site ay nasa United States |
| NCT03834753 | Phase 3 | Tapos na | Hun 7, 2021 | 228 | 50 sa 50 site ay nasa United States |
| NCT05112861 | Phase 3 | Aktibo, hindi na nagre-recruit | Dis 1, 2027 | 120 | 3 sa 3 site ay nasa United States |
| NCT03844074 | Phase 3 | Tapos na | Hul 23, 2020 | 61 | 0 sa 9 site ay nasa United States |
| NCT04516278 | Phase 3 | Tapos na | Peb 10, 2021 | 197 | 20 sa 20 site ay nasa United States |